Where Can Novel Nonviral Polymeric Delivery Agents Take Us?
Collaboration has always been an important part of scientific research and discovery, especially when you combine the resources of strategic partners in science, clinical, engineering and manufacturing.
That’s the main focus of a podcast from Cell & Gene Therapy Insights, featuring Kris Saha, Ph.D., Associate Professor at the Wisconsin Institute for Discovery, University of Wisconsin; and Tom Foti, Vice President of Aldevron’s Protein Business Unit. Working together, they and the two entities are using research tools developed in Saha’s lab to develop a streamlined path to curative therapies, as other innovative technologies provided by Aldevron serve to manufacture more efficient and safer clinical material.
In this approach, UW Labs develop new toolkits to optimize delivery systems that deal with the challenges of Phase 1 trials. Then, as trials move into Phase 2, Aldevron and its parent company, Danaher, join in as key players in the process to drive manufacturing and regulatory science for cell and gene therapy innovations.
In this podcast, Saha and Foti expand on these topics, along with how they see the future of genomic medicine developing. You can learn more details and practical examples behind how genome editing tools and non-viral delivery system are provided through the relationship of academics and industry, such as the collaboration between UW and Aldevron. Click on the player below to listen to the podcast, or download a transcript here.